Equities
Health CarePharmaceuticals and Biotechnology
  • Price (DKK)408.60
  • Today's Change-3.70 / -0.90%
  • Shares traded2.42m
  • 1 Year change+21.72%
  • Beta0.8170
Data delayed at least 15 minutes, as of May 31 2024 16:10 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Novozymes A/S is a Denmark-based biotechnology company engaged in the production and sale of industrial enzymes, microorganisms and biopharmaceutical ingredients. The Company operates in four geographical regions: Europe, Middle East & Africa (including Denmark), North America, Asia Pacific and Latin America. It develops and distributes solutions within the market areas agriculture, bioenergy, food & beverages, household care, leather, pharmaceuticals, forest products, textile and wastewater solutions. Novozymes operates through a range of partnerships with companies, such as Bayer and Syngenta in Agriculture and DSM and Adisseo in Animal Health & Nutrition..

  • Revenue in DKK (TTM)17.90bn
  • Net income in DKK3.02bn
  • Incorporated2000
  • Employees6.40k
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Azelis Group NV30.95bn1.32bn35.35bn4.21k26.171.8316.331.140.7430.74317.2910.620.78725.367.59987,214.703.593.164.463.8123.1422.444.563.881.103.890.3989--1.05---16.65------
Clariant AG33.36bn1.28bn36.43bn10.48k28.362.3510.671.090.50770.404313.286.140.75894.476.78417,612.803.691.445.492.0827.4229.654.872.251.0016.680.3823397.72-15.79-0.1229226.32-3.04-4.23-5.25
Oci NV7.59bn-6.43bn39.48bn1.15k--6.10--5.20-4.10-1.294.844.110.11324.942.00888,855.50-6.241.31-12.542.10-31.2616.86-55.113.281.55-2.550.5407---47.15-9.6110.45--12.81--
Arkema SA69.56bn2.60bn52.45bn21.10k21.770.90576.450.7544.314.31119.47103.510.64275.306.20445,478.802.565.993.177.2320.6421.463.997.591.449.910.348931.72-17.631.54-57.64-9.822.786.96
Yara International ASA100.07bn-260.54m54.21bn18.00k--1.078.000.5418-1.56-1.56599.72304.480.87633.277.348,486,911.00-0.19815.30-0.25486.9722.8426.69-0.22615.600.8922.600.365994.60-35.443.60-98.27-21.30-2.76-8.10
Imcd NV33.12bn2.18bn59.22bn4.74k27.154.6019.551.795.135.1378.0530.301.145.726.19938,057.907.497.019.869.6022.4821.406.585.801.157.980.493244.25-3.4513.30-6.6523.9124.0922.87
Evonik Industries AG112.25bn-2.65bn70.07bn33.09k--1.038.770.6242-0.7797-0.779732.5219.610.70934.327.87450,716.90-1.612.01-2.012.4218.8525.47-2.262.900.877210.340.3353130.72-17.422.85-186.27---3.510.3454
Brenntag SE121.44bn4.77bn71.02bn17.70k15.582.129.220.58484.244.24107.5231.081.508.006.30919,905.105.966.408.669.0224.3023.033.984.021.1414.890.376137.40-13.456.03-19.389.1812.47-21.40
Syensqo SA-745.47bn-745.47bn72.16bn13.05k--1.25----------73.09------------------------1.33--0.2292---13.02---79.68------
Akzo Nobel NV79.40bn3.98bn81.59bn35.50k20.522.3911.691.033.133.1062.1626.820.73523.493.91302,585.203.984.156.506.0640.7440.515.426.070.779511.340.516163.75-1.642.8823.482.2512.321.41
Novozymes A/S17.90bn3.02bn169.39bn6.40k37.558.1137.269.4610.8810.8864.4050.400.6352.204.852,798,030.0010.7813.4614.6917.8454.3255.5616.9820.120.803538.910.350238.891.974.46-17.74-1.288.114.40
Data as of May 31 2024. Currency figures normalised to Novozymes A/S's reporting currency: Danish Krone DKK

Institutional shareholders

14.66%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 09 May 202412.44m3.00%
Norges Bank Investment Managementas of 31 Dec 20238.85m2.13%
APG Asset Management NVas of 31 Dec 20227.67m1.85%
BlackRock Fund Advisorsas of 09 May 20246.03m1.46%
GuardCap Asset Management Ltd.as of 31 Mar 20245.23m1.26%
Impax Asset Management Ltd.as of 30 Apr 20245.06m1.22%
Handelsbanken Fonder ABas of 30 Apr 20244.42m1.07%
MFS International (UK) Ltd.as of 30 Apr 20244.04m0.97%
Baillie Gifford & Co.as of 30 Apr 20243.76m0.91%
Pictet Asset Management SAas of 30 Apr 20243.26m0.79%
More ▼
Data from 31 Dec 2023 - 30 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.